Emerging data on nivolumab for esophageal squamous cell carcinoma.
Toshiharu HiroseShun YamamotoKen KatoPublished in: Expert review of gastroenterology & hepatology (2021)
Nivolumab has been approved by the US Food and Drug Administration for treatment after prior chemotherapy in patients with advanced ESCC. Several trials evaluating nivolumab-containing treatments are ongoing in patients with not only advanced EC, but also locally advanced EC, and these investigational treatments might improve the clinical outcomes of EC patients.